158 related articles for article (PubMed ID: 36842467)
1. MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy.
He K; Berz D; Gadgeel SM; Iams WT; Bruno DS; Blakely CM; Spira AI; Patel MR; Waterhouse DM; Richards DA; Pham A; Jotte R; Hong DS; Garon EB; Traynor A; Olson P; Latven L; Yan X; Shazer R; Leal TA
J Thorac Oncol; 2023 Jul; 18(7):907-921. PubMed ID: 36842467
[TBL] [Abstract][Full Text] [Related]
2. SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer.
Borghaei H; de Marinis F; Dumoulin D; Reynolds C; Theelen WSME; Percent I; Gutierrez Calderon V; Johnson ML; Madroszyk-Flandin A; Garon EB; He K; Planchard D; Reck M; Popat S; Herbst RS; Leal TA; Shazer RL; Yan X; Harrigan R; Peters S;
Ann Oncol; 2024 Jan; 35(1):66-76. PubMed ID: 37866811
[TBL] [Abstract][Full Text] [Related]
3. A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma.
Msaouel P; Sweis RF; Bupathi M; Heath E; Goodman OB; Hoimes CJ; Milowsky MI; Davis N; Kalebasty AR; Picus J; Shaffer D; Mao S; Adra N; Yorio J; Gandhi S; Grivas P; Siefker-Radtke A; Yang R; Latven L; Olson P; Chin CD; Der-Torossian H; Mortazavi A; Iyer G
Eur Urol Oncol; 2023 Dec; ():. PubMed ID: 38105142
[TBL] [Abstract][Full Text] [Related]
4. Antitumor immune effects of preoperative sitravatinib and nivolumab in oral cavity cancer: SNOW window-of-opportunity study.
Oliva M; Chepeha D; Araujo DV; Diaz-Mejia JJ; Olson P; Prawira A; Spreafico A; Bratman SV; Shek T; de Almeida J; R Hansen A; Hope A; Goldstein D; Weinreb I; Smith S; Perez-Ordoñez B; Irish J; Torti D; Bruce JP; Wang BX; Fortuna A; Pugh TJ; Der-Torossian H; Shazer R; Attanasio N; Au Q; Tin A; Feeney J; Sethi H; Aleshin A; Chen I; Siu L
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599023
[TBL] [Abstract][Full Text] [Related]
5. First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors.
Bauer T; Cho BC; Heist R; Bazhenova L; Werner T; Goel S; Kim DW; Adkins D; Carvajal RD; Alva A; Eaton K; Wang J; Liu Y; Yan X; Christensen J; Neuteboom S; Chao R; Pant S
Invest New Drugs; 2022 Oct; 40(5):990-1000. PubMed ID: 35767205
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of multi-target TKI combined with nivolumab in check-point inhibitor-refractory patients with advanced NSCLC: a prospective, single-arm, two-stage study.
Zhang B; Liu H; Shi C; Gao Z; Zhong R; Gu A; Chu T; Wang H; Xiong L; Zhang W; Zhang X; Yan B; Teng J; Wang W; Bai H; Qiao R; Cheng L; Kuang Y; Zhao R; Zhong H; Han B
BMC Cancer; 2024 Jun; 24(1):715. PubMed ID: 38862908
[TBL] [Abstract][Full Text] [Related]
7. Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination With Pegilodecakin in Patients With Metastatic NSCLC (CYPRESS 1 and CYPRESS 2).
Spigel D; Jotte R; Nemunaitis J; Shum M; Schneider J; Goldschmidt J; Eisenstein J; Berz D; Seneviratne L; Socoteanu M; Bhanderi V; Konduri K; Xia M; Wang H; Hozak RR; Gueorguieva I; Ferry D; Gandhi L; Chao BH; Rybkin I
J Thorac Oncol; 2021 Feb; 16(2):327-333. PubMed ID: 33166722
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study.
Amin A; Plimack ER; Ernstoff MS; Lewis LD; Bauer TM; McDermott DF; Carducci M; Kollmannsberger C; Rini BI; Heng DYC; Knox J; Voss MH; Spratlin J; Berghorn E; Yang L; Hammers HJ
J Immunother Cancer; 2018 Oct; 6(1):109. PubMed ID: 30348216
[TBL] [Abstract][Full Text] [Related]
9. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.
Borghaei H; Gettinger S; Vokes EE; Chow LQM; Burgio MA; de Castro Carpeno J; Pluzanski A; Arrieta O; Frontera OA; Chiari R; Butts C; Wójcik-Tomaszewska J; Coudert B; Garassino MC; Ready N; Felip E; García MA; Waterhouse D; Domine M; Barlesi F; Antonia S; Wohlleber M; Gerber DE; Czyzewicz G; Spigel DR; Crino L; Eberhardt WEE; Li A; Marimuthu S; Brahmer J
J Clin Oncol; 2021 Mar; 39(7):723-733. PubMed ID: 33449799
[TBL] [Abstract][Full Text] [Related]
10. SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer.
Zhao J; Yu X; Huang D; Ma Z; Gao B; Cui J; Chu Q; Zhou Q; Sun M; Day D; Wu J; Pan H; Wang L; Voskoboynik M; Wang Z; Liu Y; Li H; Zhang J; Peng Y; Wu YL
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36808075
[TBL] [Abstract][Full Text] [Related]
11. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma.
Karam JA; Msaouel P; Haymaker CL; Matin SF; Campbell MT; Zurita AJ; Shah AY; Wistuba II; Marmonti E; Duose DY; Parra ER; Soto LMS; Laberiano-Fernandez C; Lozano M; Abraham A; Hallin M; Chin CD; Olson P; Der-Torossian H; Yan X; Tannir NM; Wood CG
Nat Commun; 2023 May; 14(1):2684. PubMed ID: 37164948
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Limertinib (ASK120067) in Patients With Locally Advanced or Metastatic EGFR Thr790Met-Mutated NSCLC: A Multicenter, Single-Arm, Phase 2b Study.
Shi Y; Li B; Wu L; Pan Y; Pan Z; Liu Y; Fan Y; Ji Y; Fang J; Shi Q; Shi J; Gao H; Hu Y; Wang X; He Z; Ma R; Zhang Y; Jiang D; Bai Y; Zhang Y; Huang L; Zhou T; Liu H; Wang D; Wen Q; Chen G; Zang A; Wang X; Zhang X; Hu J; Yang R; Zhang G; Gu K; Wang L; Wang Q; Wei Z; Li Z; Lu H; Zhang H; Chen H; Song T
J Thorac Oncol; 2022 Oct; 17(10):1205-1215. PubMed ID: 35659581
[TBL] [Abstract][Full Text] [Related]
14. Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial.
Gettinger SN; Redman MW; Bazhenova L; Hirsch FR; Mack PC; Schwartz LH; Bradley JD; Stinchcombe TE; Leighl NB; Ramalingam SS; Tavernier SS; Yu H; Unger JM; Minichiello K; Highleyman L; Papadimitrakopoulou VA; Kelly K; Gandara DR; Herbst RS
JAMA Oncol; 2021 Sep; 7(9):1368-1377. PubMed ID: 34264316
[TBL] [Abstract][Full Text] [Related]
15. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial.
Wu YL; Lu S; Cheng Y; Zhou C; Wang J; Mok T; Zhang L; Tu HY; Wu L; Feng J; Zhang Y; Luft AV; Zhou J; Ma Z; Lu Y; Hu C; Shi Y; Baudelet C; Cai J; Chang J
J Thorac Oncol; 2019 May; 14(5):867-875. PubMed ID: 30659987
[TBL] [Abstract][Full Text] [Related]
16. Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC.
Gettinger S; Hellmann MD; Chow LQM; Borghaei H; Antonia S; Brahmer JR; Goldman JW; Gerber DE; Juergens RA; Shepherd FA; Laurie SA; Young TC; Li X; Geese WJ; Rizvi N
J Thorac Oncol; 2018 Sep; 13(9):1363-1372. PubMed ID: 29802888
[TBL] [Abstract][Full Text] [Related]
17. Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects.
Peters S; Paz-Ares L; Herbst RS; Reck M
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35858709
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.
Rizvi NA; Hellmann MD; Brahmer JR; Juergens RA; Borghaei H; Gettinger S; Chow LQ; Gerber DE; Laurie SA; Goldman JW; Shepherd FA; Chen AC; Shen Y; Nathan FE; Harbison CT; Antonia S
J Clin Oncol; 2016 Sep; 34(25):2969-79. PubMed ID: 27354481
[TBL] [Abstract][Full Text] [Related]
19. A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer.
Nadal E; Saleh M; Aix SP; Ochoa-de-Olza M; Patel SP; Antonia S; Zhao Y; Gueorguieva I; Man M; Estrem ST; Liu J; Avsar E; Lin WH; Benhadji KA; Gandhi L; Guba SC; Diaz IA
BMC Cancer; 2023 Jul; 23(1):708. PubMed ID: 37507657
[TBL] [Abstract][Full Text] [Related]
20. Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817.
Paz-Ares LG; Ciuleanu TE; Pluzanski A; Lee JS; Gainor JF; Otterson GA; Audigier-Valette C; Ready N; Schenker M; Linardou H; Caro RB; Provencio M; Zurawski B; Lee KH; Kim SW; Caserta C; Ramalingam SS; Spigel DR; Brahmer JR; Reck M; O'Byrne KJ; Girard N; Popat S; Peters S; Memaj A; Nathan F; Aanur N; Borghaei H
J Thorac Oncol; 2023 Jan; 18(1):79-92. PubMed ID: 36049658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
